We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+9.35%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$6.46B
AUM Growth
-$2.68M
Cap. Flow
-$148M
Cap. Flow %
-2.29%
Top 10 Hldgs %
39.36%
Holding
145
New
22
Increased
28
Reduced
21
Closed
17

Top Buys

Rank Stock Value
1
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$201M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$91.6M
3
QURE icon
uniQure
QURE
+$57.2M
4
NTRA icon
Natera
NTRA
+$47.4M
5
ATNX
Athenex, Inc. Common Stock
ATNX
+$47.3M

Top Sells

Rank Stock Value
1
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$272M
2
GH icon
Guardant Health
GH
+$118M
3
VTRS icon
Viatris
VTRS
+$77.1M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$64M
5
HUM icon
Humana
HUM
+$55.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.94%
2 Miscellaneous 1.85%
3 Financials 1.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARNA
101
DELISTED
Arena Pharmaceuticals Inc
ARNA
$6.45M 0.1%
+110,000
New +$5.69M
BMRN icon
102
BioMarin Pharmaceuticals
BMRN
$12.9B
$6.42M 0.1%
75,000
-1,500
-2% -$128K
BMRN icon
103
PUT
BioMarin Pharmaceuticals
BMRN
$12.9B
$6.42M 0.1%
75,000
-175,000
-70% -$15M
VRNA
104
DELISTED
Verona Pharma
VRNA
$6.38M 0.1%
1,250,396
– –
XENE icon
105
Xenon Pharmaceuticals
XENE
$5.64B
$6.26M 0.1%
634,812
– –
SPRO icon
106
Spero Therapeutics
SPRO
$65.8M
$5.84M 0.09%
507,471
– –
ADPT icon
107
Adaptive Biotechnologies
ADPT
$3.86B
$5.8M 0.09%
+120,000
New +$5.32M
MDCO
108
DELISTED
Medicines Co
MDCO
$5.53M 0.09%
+151,515
New +$4.95M
ADAP
109
DELISTED
Adaptimmune Therapeutics
ADAP
$5.43M 0.08%
1,350,655
– –
NTLA icon
110
Intellia Therapeutics
NTLA
$1.66B
$5.36M 0.08%
327,600
-50,000
-13% -$786K
RNAC icon
111
Cartesian Therapeutics
RNAC
$248M
$5.15M 0.08%
95,969
– –
RARE icon
112
Ultragenyx Pharmaceutical
RARE
$1.34B
$5.05M 0.08%
+79,607
New +$5.07M
WHWK
113
Whitehawk Therapeutics
WHWK
$234M
$4.73M 0.07%
346,263
– –
CTIC
114
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$4.3M 0.07%
5,000,000
– –
YARW
115
Yarrow Bioscience
YARW
$72.1M
$4.04M 0.06%
187
+11
+6% +$272K
STOK icon
116
Stoke Therapeutics
STOK
$1.87B
$3.79M 0.06%
+130,000
New +$3.49M
ELDN icon
117
Eledon Pharmaceuticals
ELDN
$225M
$3.21M 0.05%
176,851
+35,900
+25% +$1.57M
RLM
118
DELISTED
Realm Therapeutics plc American Depositary Shares
RLM
$2.87M 0.04%
1,021,484
– –
ACAD icon
119
Acadia Pharmaceuticals
ACAD
$4.74B
$2.72M 0.04%
+101,900
New +$2.6M
DVAX
120
DELISTED
Dynavax Technologies
DVAX
$2.33M 0.04%
+583,500
New +$3.38M
SNDX icon
121
Syndax Pharmaceuticals
SNDX
$1.62B
$1.97M 0.03%
212,000
– –
APLS
122
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$1.9M 0.03%
75,000
– –
TECX
123
Tectonic Therapeutic
TECX
$568M
$1.72M 0.03%
8,833
-7,716
-47% -$1.66M
MRNS
124
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.65M 0.03%
99,525
– –
NVTR
125
DELISTED
Nuvectra Corporation Common Stock
NVTR
$1.17M 0.02%
350,000
– –
2 3 4
5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2019 Portfolio in Review

As of Q2 2019, OrbiMed held 145 positions worth $6.46B, down 0.04% from $6.46B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

OrbiMed's Q2 2019 filing shows 22 new, 28 increased, 21 reduced and 17 closed positions. Its largest new stake was Prevail Therapeutics Inc. Common Stock: 13,822,463 shares worth $182M. The largest sale was Clementia Pharmaceuticals Inc., an estimated $272M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Financials.

  • OrbiMed's largest Q2 2019 buy was Prevail Therapeutics Inc. Common Stock: 13,822,463 shares worth $182M.
  • OrbiMed added most to Natera in Q2 2019, an estimated $47.4M increase.
  • OrbiMed's biggest Q2 2019 reduction was Viatris, cutting an estimated $77.1M.
  • OrbiMed fully exited Clementia Pharmaceuticals Inc. in Q2 2019, selling an estimated $272M.
  • OrbiMed's ten largest holdings make up 39% of its $6.46B portfolio in Q2 2019.
  • OrbiMed opened 22 new positions and closed 17 in Q2 2019.
  • OrbiMed's portfolio value fell 0.04% quarter-over-quarter to $6.46B.

Based on OrbiMed's 13F filing for Q2 2019, filed 14 Aug 2019.